{"id":46117,"date":"2017-03-21T23:33:29","date_gmt":"2017-03-22T04:33:29","guid":{"rendered":"https:\/\/3768346-fork.findlaw4.flsitebuilder.com\/?p=46117"},"modified":"2017-03-21T23:33:29","modified_gmt":"2017-03-22T04:33:29","slug":"the-seiden-group-announces-u-s-shareholders-formation-of-a-group-to-recover-investor-funds-through-a-possible-receivership-over-china-based-huifeng-bio-pharmaceutical-technology-inc-ticker_-hfgb","status":"publish","type":"post","link":"https:\/\/seidenlaw.com\/he\/blog\/2017\/03\/the-seiden-group-announces-u-s-shareholders-formation-of-a-group-to-recover-investor-funds-through-a-possible-receivership-over-china-based-huifeng-bio-pharmaceutical-technology-inc-ticker_-hfgb\/","title":{"rendered":"\u05d7\u05d5\u05e7 \u05e1\u05d9\u05d3\u05df \u05de\u05db\u05e8\u05d9\u05d6 \u05e2\u05dc \u05d4\u05e7\u05de\u05ea \u05e7\u05d1\u05d5\u05e6\u05ea \u05d1\u05e2\u05dc\u05d9 \u05de\u05e0\u05d9\u05d5\u05ea \u05d1\u05d0\u05e8\u05d4\"\u05d1 \u05db\u05d3\u05d9 \u05dc\u05d4\u05e9\u05d9\u05d1 \u05d0\u05ea \u05db\u05e1\u05e4\u05d9 \u05d4\u05de\u05e9\u05e7\u05d9\u05e2\u05d9\u05dd \u05d1\u05d0\u05de\u05e6\u05e2\u05d5\u05ea \u05d4\u05dc\u05d9\u05db\u05d9 \u05e7\u05d1\u05dc\u05ea \u05d4\u05d0\u05d7\u05e8\u05d9\u05d5\u05ea \u05d4\u05d0\u05e4\u05e9\u05e8\u05d9\u05ea \u05e0\u05d2\u05d3 \u05d7\u05d1\u05e8\u05ea Huifeng Bio-Pharmaceutical Technology, Inc \u05d4\u05de\u05de\u05d5\u05e7\u05de\u05ea \u05d1\u05e1\u05d9\u05df (\u05e1\u05d9\u05de\u05d5\u05dc_ HFGB)"},"content":{"rendered":"<p><strong>Huifeng Bio-Pharmaceutical Technology, Inc.\u00a0<\/strong>(Ticker: HFGB), is a\u00a0British Virgin Islands\u00a0corporation involved in the business of manufacturing and marketing pharmaceutical raw materials and ingredients, such as pharmaceuticals used for human and animals, nutraceuticals, cosmetics, functional drink and food. HFGB was de-listed from the NASDAQ in\u00a0January 2013\u00a0after it stopped reporting to the Securities &amp; Exchange Commission (\u201cSEC\u201d).<\/p>\n<p>\u05d7\u05dc\u05e7 \u05de\u05d4\u05d1\u05e2\u05dc\u05d9\u05dd \u05d3\u05d9\u05d1\u05e8\u05d5 \u05e2\u05dd \u05e8\u05d5\u05d1\u05e8\u05d8 \u05d5. \u05e1\u05d9\u05d9\u05d3\u05df, \u05e2\u05d5\u05e8\u05da \u05d3\u05d9\u05df \u05d1\u05e0\u05d9\u05d5 \u05d9\u05d5\u05e8\u05e7, \u05db\u05d3\u05d9 \u05dc\u05d9\u05d9\u05e6\u05d2 \u05e7\u05d1\u05d5\u05e6\u05ea \u05d1\u05e2\u05dc\u05d9\u05dd \u05d5\u05dc\u05d3\u05e8\u05d5\u05e9 \u05d0\u05ea \u05d6\u05db\u05d5\u05d9\u05d5\u05ea\u05d9\u05d4\u05dd \u05e9\u05dc \u05d1\u05e2\u05dc\u05d9 \u05d4\u05de\u05e0\u05d9\u05d5\u05ea \u05d1\u05d0\u05e8\u05e6\u05d5\u05ea \u05d4\u05d1\u05e8\u05d9\u05ea \u05d1\u05d2\u05d9\u05df \u05de\u05e2\u05e9\u05d9\u05dd \u05d4\u05de\u05d6\u05d9\u05e7\u05d9\u05dd \u05dc\u05de\u05e9\u05e7\u05d9\u05e2\u05d9\u05dd, \u05db\u05d5\u05dc\u05dc \u05d0\u05d9-\u05d3\u05d9\u05d5\u05d5\u05d7 \u05dc-SEC \u05e2\u05dc \u05de\u05e0\u05ea \u05dc\u05e7\u05d1\u05dc \u05d4\u05d7\u05d6\u05e8 \u05d0\u05e4\u05e9\u05e8\u05d9 \u05e9\u05dc \u05d4\u05d4\u05d5\u05df \u05dc\u05de\u05e9\u05e7\u05d9\u05e2\u05d9\u05dd.<\/p>\n<p><a href=\"https:\/\/www.prnewswire.com\/news-releases\/the-seiden-group-announces-us-shareholders-formation-of-a-group-to-recover-investor-funds-through-a-possible-receivership-over-china-based-huifeng-bio-pharmaceutical-technology-inc-ticker-hfgb-300427371.html\" target=\"_blank\" rel=\"noopener\">\u05dc\u05e7\u05e8\u05d9\u05d0\u05d4 \u05e0\u05d5\u05e1\u05e4\u05ea<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Huifeng Bio-Pharmaceutical Technology, Inc. (\u05e1\u05d9\u05de\u05d5\u05dc: HFGB), \u05d4\u05d9\u05d0 \u05d7\u05d1\u05e8\u05d4 \u05d1\u05d1\u05e7\u05e8\u05ea \u05d0\u05d9\u05d9 \u05d4\u05d1\u05ea\u05d5\u05dc\u05d4 \u05d4\u05d1\u05e8\u05d9\u05d8\u05d9\u05ea \u05d4\u05e2\u05d5\u05e1\u05e7\u05ea \u05d1\u05e2\u05e1\u05e7\u05d9 \u05d9\u05d9\u05e6\u05d5\u05e8 \u05d5\u05e9\u05d9\u05d5\u05d5\u05e7 \u05e9\u05dc \u05d7\u05d5\u05de\u05e8\u05d9 \u05d2\u05dc\u05dd \u05d5\u05ea\u05d5\u05e1\u05e4\u05d9\u05dd \u05ea\u05e8\u05d5\u05e4\u05ea\u05d9\u05d9\u05dd, \u05db\u05d2\u05d5\u05df \u05ea\u05e8\u05d5\u05e4\u05d5\u05ea\u2026<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-46117","post","type-post","status-publish","format-standard","hentry","category-firm-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/seidenlaw.com\/he\/wp-json\/wp\/v2\/posts\/46117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seidenlaw.com\/he\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/seidenlaw.com\/he\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/seidenlaw.com\/he\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/seidenlaw.com\/he\/wp-json\/wp\/v2\/comments?post=46117"}],"version-history":[{"count":0,"href":"https:\/\/seidenlaw.com\/he\/wp-json\/wp\/v2\/posts\/46117\/revisions"}],"wp:attachment":[{"href":"https:\/\/seidenlaw.com\/he\/wp-json\/wp\/v2\/media?parent=46117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/seidenlaw.com\/he\/wp-json\/wp\/v2\/categories?post=46117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/seidenlaw.com\/he\/wp-json\/wp\/v2\/tags?post=46117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}